NewcelX (NCEL) Operating Leases (2022 - 2023)
NewcelX (NCEL) posted quarterly Operating Leases of $164000.0 for Q2 2023, down 63.06% quarter-over-quarter from $444000.0 in Q4 2022.
NewcelX (NCEL) Operating Leases (2022 - 2023) Analysis & Trends
NewcelX (NCEL) has reported Operating Leases for 2 consecutive years, with $164000.0 the latest figure, recorded in Q2 2023.
- In Q2 2023, Operating Leases changed N/A year-over-year to $164000.0; the TTM figure through Jun 2023 stood at $164000.0 (changed N/A YoY), while the FY2022 annual figure was $444000.0, changed N/A from the prior year.
- Operating Leases eased to $164000.0 in Q2 2023 per NCEL's latest filing, from $444000.0 in the prior quarter.
- Across five years, Operating Leases topped out at $444000.0 in Q4 2022 and bottomed at $164000.0 in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.69 Bn | 131.84 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.46 Bn | 78.47 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.62 Bn | 60.44 Bn | 1.37 Bn |
| 4 | Moderna | 58.37 Bn | 53.24 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.73 Bn | 28.43 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.27 Bn | 9.87 Bn | 668.28 Mn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.23 Bn | 26.40 Bn | - |
| 10 | NewcelX | 12.65 Mn | 10.45 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 164,000.00 |
| Dec 31, 2022 | 444,000.00 |